Personal Capital Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$478K Hold
8,404
﹤0.01% 310
2022
Q3
$332K Hold
8,404
﹤0.01% 339
2022
Q2
$370K Hold
8,404
﹤0.01% 308
2022
Q1
$335K Sell
8,404
-1,503
-15% -$53.5K ﹤0.01% 366
2021
Q4
$398K Hold
9,907
﹤0.01% 377
2021
Q3
$403K Hold
9,907
﹤0.01% 343
2021
Q2
$450K Hold
9,907
﹤0.01% 326
2021
Q1
$413K Sell
9,907
-847
-8% -$38.7K ﹤0.01% 332
2020
Q4
$459K Buy
10,754
+2
+0% +$72 ﹤0.01% 314
2020
Q3
$283K Hold
10,752
﹤0.01% 338
2020
Q2
$288K Buy
+10,752
New +$243K ﹤0.01% 294

Other funds holding HALO

Personal Capital Advisors's HALO Position: Q4 2022 in Review

Personal Capital Advisors held its Halozyme (HALO) position steady in Q4 2022 at 8,404 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #310.

Personal Capital Advisors first reported a position in HALO in Q2 2020 and has held it in 11 quarters since. 422 funds tracked by Wall St. Rank hold HALO as of Q4 2022.

  • Personal Capital Advisors held 8,404 shares of Halozyme worth $478K as of Q4 2022.
  • Personal Capital Advisors left its Halozyme share count unchanged in Q4 2022.
  • Halozyme made up ﹤0.01% of Personal Capital Advisors's portfolio in Q4 2022, its #310 holding.
  • Personal Capital Advisors first reported a position in Halozyme in Q2 2020 and has held it in 11 quarters since.
  • 422 funds tracked by Wall St. Rank held Halozyme as of Q4 2022.

Based on Personal Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.